Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors

NCT04588324 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: SHR2150
DRUG: Anti-Cancer Agent
DRUG: SHR2150

Sponsor

Chinese PLA General Hospital